Gilead Sciences, Inc.
Ticker
GILD
ISIN
US3755581036
Price
USD 91.96
Change Today
-0.67 / -0.723 %
Price 1 year ago
72.89 / 26.165 %
Market Capitalization
99,434,700,800.00
52 Week Low
62.08
52 Week High
97.90
200 Day Moving Average
73.78
50-day Moving Average
86.41
Price evolution
Yearly Returns
Peers
Peers
Company information
Summary
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Sector
Healthcare
Industry
Drug Manufacturers—General
Country
United States
Exchange
NMS
Earnings Per Share
0.24
P/E Ratio
330.29166
Debt/Equity Ratio
131.599
Beta
0.39123
Ebitda
13,226,999,808.00
Ebitda Margins
0.48
Enterprise to Ebitda
7.19
Enterprise Value
95,124,226,048.00
Target Price
69.48
Estimated Price
-
Book Value
15.12
Expected Growth
-
Balance sheet
Income statement
Sustainability
Correlation
| Company | Name | Correlation |
|---|---|---|
| 600436.SS | ZHANGZHOU PIENTZEHUANG PHARMACE | -0.19 |
| 4519.T | CHUGAI PHARMACEUTICAL CO | -0.07 |
| 600867.SS | TONGHUA DONGBAO MEDICINES CO LT | -0.05 |
| MYX.AX | M PHARMA FPO | -0.00 |
| 600276.SS | JIANGSU HENGRUI MEDICAL CO LTD | 0.07 |
| 600771.SS | GUANGYUYUAN CHINESE HERBAL MEDI | 0.08 |
| 600713.SS | NANJING PHARMACEUTICAL CO LTD | 0.17 |
| 2186.HK | LUYE PHARMA | 0.21 |
| 4503.T | ASTELLAS PHARMA | 0.22 |
| HZNP | Horizon Therapeutics Public Lim | 0.22 |
| BMY | Bristol-Myers Squibb Company | 0.24 |
| 600572.SS | ZHEJIANG CONBA PHARMACEUTICAL C | 0.28 |
| ABBV | AbbVie Inc. | 0.28 |
| 1093.HK | CSPC PHARMA | 0.29 |
| 300006.SZ | CHONGQING LUMMY PH | 0.29 |
| AZN | Astrazeneca PLC | 0.30 |
| LLY | Eli Lilly and Company | 0.30 |
| GSK.L | GSK PLC | 0.30 |
| 4568.T | DAIICHI SANKYO COMPANY LIMITED | 0.34 |
| JNJ | Johnson & Johnson | 0.36 |
| ECILC.IS | ECZACIBASI ILAC | 0.37 |
| SNY | Sanofi | 0.40 |
| GSK | GSK plc | 0.41 |
| KLBF.JK | Kalbe Farma Tbk. | 0.43 |
| NOVN.SW | NOVARTIS N | 0.43 |
| 600613.SS | SHANGHAI SHENQI PHARM INVEST MA | 0.48 |
| PFE | Pfizer, Inc. | 0.50 |
| MRK | Merck & Company, Inc. | 0.57 |
| AMGN | Amgen Inc. | 0.63 |
Similar companies
| Ticker | Name | City | Country | Currency | Exchange | Beta | EV/EBITDA | Employees | Site |
|---|---|---|---|---|---|---|---|---|---|
| 600276.SS | JIANGSU HENGRUI MEDICAL CO LTD | Lianyungang | China | CNY | SHH | 58.73 | 24491 | https://www.hrs.com.cn | |
| KLBF.JK | Kalbe Farma Tbk. | Jakarta | Indonesia | IDR | JKT | 0.50 | 14.50 | 12392 | https://www.kalbe.co.id |
| 1093.HK | CSPC PHARMA | Shijiazhuang | China | HKD | HKG | 0.67 | 12.86 | 24746 | https://www.cspc.com.hk |
| 300006.SZ | CHONGQING LUMMY PH | Chongqing | China | CNY | SHZ | 0.83 | -32.33 | 935 | https://www.cqlummy.com |
| PFE | Pfizer, Inc. | New York | United States | USD | NYQ | 0.68 | 6.88 | 79000 | https://www.pfizer.com |
| 600572.SS | ZHEJIANG CONBA PHARMACEUTICAL C | Hangzhou | China | CNY | SHH | 0.46 | 10.69 | 8589 | https://www.conbagroup.com |
| 600713.SS | NANJING PHARMACEUTICAL CO LTD | Nanjing | China | CNY | SHH | 0.46 | 9.37 | 5062 | https://www.njyy.com |
| 600867.SS | TONGHUA DONGBAO MEDICINES CO LT | Tonghua | China | CNY | SHH | 0.24 | 12.42 | https://www.thdb.com | |
| ECILC.IS | ECZACIBASI ILAC | Istanbul | Turkey | TRY | IST | 0.20 | 71.70 | 336 | https://www.eczacibasi.com.tr/en/eczacibasi-gruop/companies/other-products-and-services |
| GSK.L | GSK PLC | Brentford | United Kingdom | GBp | LSE | 0.32 | 6.22 | 90096 | https://www.gsk.com |
| MRK | Merck & Company, Inc. | Kenilworth | United States | USD | NYQ | 0.36 | 10.37 | 67000 | https://www.merck.com |
| BMY | Bristol-Myers Squibb Company | New York | United States | USD | NYQ | 0.44 | 8.87 | 32200 | https://www.bms.com |
| 600771.SS | GUANGYUYUAN CHINESE HERBAL MEDI | Xi'an | China | CNY | SHH | 0.55 | -48.11 | 1900 | https://www.guangyuyuan.com |
| GILD | Gilead Sciences, Inc. | Foster City | United States | USD | NMS | 0.39 | 7.19 | 14400 | https://www.gilead.com |
| JNJ | Johnson & Johnson | New Brunswick | United States | USD | NYQ | 0.57 | 14.45 | 141700 | https://www.jnj.com |
| GSK | GSK plc | Brentford | United Kingdom | USD | NYQ | 0.18 | 8.08 | 90096 | https://www.gsk.com |
| AZN | Astrazeneca PLC | Cambridge | United Kingdom | USD | NMS | 0.12 | 18.55 | 83100 | https://www.astrazeneca.com |
| ABBV | AbbVie Inc. | North Chicago | United States | USD | NYQ | 0.75 | 11.46 | 50000 | https://www.abbvie.com |
| 2186.HK | LUYE PHARMA | Yantai | China | HKD | HKG | 0.75 | 14.06 | 4845 | https://www.luye.cn |
| 600613.SS | SHANGHAI SHENQI PHARM INVEST MA | Shanghai | China | CNY | SHH | 0.36 | 22.96 | 1371 | https://www.gzsq.com |
| MYX.AX | M PHARMA FPO | Salisbury South | Australia | AUD | ASX | 1.09 | 27.98 | https://www.maynepharma.com | |
| 4568.T | DAIICHI SANKYO COMPANY LIMITED | Tokyo | Japan | JPY | JPX | 52.12 | 16458 | https://www.daiichisankyo.com | |
| 4503.T | ASTELLAS PHARMA | Tokyo | Japan | JPY | JPX | 0.58 | 12.39 | 14522 | https://www.astellas.com |
| NOVN.SW | NOVARTIS N | Basel | Switzerland | CHF | EBS | 0.50 | 10.30 | 108000 | https://www.novartis.com |
| SNY | Sanofi | Paris | France | USD | NMS | 0.36 | 9.75 | 95442 | https://www.sanofi.com |
| HZNP | Horizon Therapeutics Public Lim | Dublin | Ireland | USD | NMS | 1.16 | 20.67 | 1940 | https://www.horizontherapeutics.com |
| LLY | Eli Lilly and Company | Indianapolis | United States | USD | NYQ | 0.37 | 29.00 | 35000 | https://www.lilly.com |
| AMGN | Amgen Inc. | Thousand Oaks | United States | USD | NMS | 0.58 | 12.61 | 24200 | https://www.amgen.com |
| 4519.T | CHUGAI PHARMACEUTICAL CO | Tokyo | Japan | JPY | JPX | 0.64 | 9.60 | 7664 | https://www.chugai-pharm.co.jp |
| 600436.SS | ZHANGZHOU PIENTZEHUANG PHARMACE | Zhangzhou | China | CNY | SHH | 0.78 | 57.53 | 2591 | https://www.zzpzh.com.cn |
| BAYN.DE | BAYER AG | Leverkusen | Germany | EUR | GER | 1.16 | 13.66 | 101914 | https://www.bayer.com |
| AZN.L | ASTRAZENECA PLC ORD SHS $0.25 | Cambridge | United Kingdom | GBp | LSE | 0.10 | 15.96 | 83100 | https://www.astrazeneca.com |
| 300357.SZ | ZHEJIANG WOLWO BIO | Huzhou | China | CNY | SHZ | 0.40 | 56.57 | 1488 | https://www.wolwobiotech.com |
| SAN.PA | SANOFI | Paris | France | EUR | PAR | 0.36 | 9.86 | 95442 | https://www.sanofi.com |
| NVS | Novartis AG | Basel | Switzerland | USD | NYQ | 0.49 | 10.62 | 108000 | https://www.novartis.com |
| 0P6S.IL | BAYER AG | Leverkusen | Germany | EUR | IOB | 1.15 | 9.51 | 100753 | https://www.bayer.com |
| CIPLA.NS | CIPLA LTD | Mumbai | India | INR | NSI | 17.91 | https://www.cipla.com | ||
| 4528.T | ONO PHARMACEUTICAL CO | Osaka | Japan | JPY | JPX | 0.33 | 13.40 | 3687 | https://www.ono-pharma.com |
| 4536.T | SANTEN PHARMACEUTICAL CO | Osaka | Japan | JPY | JPX | 0.37 | 7.05 | 4315 | https://www.santen.com |
| OGN | Organon & Co. | Jersey City | United States | USD | NYQ | 7.83 | 9300 | https://www.organon.com |
Funds
Mutual Fund Holders
Social
Dividends
Ratings
News
Earnings
SEC Filings
Options
Indicators
Glossary
- Momentum
- A technical indicator that measures the rate of change in price movements over a specific period. It indicates the strength or weakness of a price trend.
Assessment: A positive momentum value generally indicates a good trend, while a negative value suggests a weak or downward trend.
- Inertia
- In trading, inertia refers to the tendency of prices to continue moving in their current direction. It suggests that an asset's price will likely maintain its current trend.
Assessment: A higher inertia value is generally considered good, as it indicates a strong and sustained price trend.
- Relative Strength Index (RSI)
- A momentum oscillator that measures the speed and change of price movements. It helps identify overbought or oversold conditions in an asset.
Assessment: An RSI value above 70 is typically considered overbought and may suggest a potential reversal or correction. Conversely, an RSI value below 30 is often considered oversold, indicating a possible upward price correction.
- Fibonacci's Weighted Moving Average
- A technical indicator that assigns different weights to recent data points, giving more significance to recent prices. It helps smooth out price fluctuations and identify trend reversals.
Assessment: The interpretation of the Fibonacci's Weighted Moving Average value depends on its comparison to other moving averages or trendlines. A value above 50 may indicate an uptrend, while a value below 50 may suggest a downtrend.
- Williams %R
- A momentum indicator that measures overbought or oversold conditions in an asset. It shows the relationship of the current closing price to the high-low range over a specified period.
Assessment: Williams %R values above -20 are typically considered overbought and may indicate a potential price reversal. Values below -80 are often viewed as oversold, suggesting a potential price bounce.
- Relative Volatility Index (RVI)
- A technical indicator that measures the volatility of a security by comparing the magnitude of recent price movements to the magnitude of average price changes. It helps identify periods of high or low volatility.
Assessment: A higher RVI value suggests higher volatility, which can provide trading opportunities but also carries increased risk.
- Commodity Channel Index (CCI)
- A versatile indicator that measures the current price level relative to an average price level over a given period. It helps identify overbought or oversold conditions and potential trend reversals.
Assessment: CCI values above 100 are often considered overbought, indicating a potential price correction or reversal. Values below -100 are typically viewed as oversold, suggesting a potential price rebound.